What are the side effects of flucytosine and amphotericin B when used to treat a central nervous system fungal infection such as a dural abscess?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Side Effects of Amphotericin B and Flucytosine for CNS Fungal Infections

The combination of amphotericin B and flucytosine for CNS fungal infections carries significant toxicity risks, with nephrotoxicity and bone marrow suppression being the most clinically important adverse effects that require intensive monitoring.

Major Side Effects by Drug

Amphotericin B Side Effects

Nephrotoxicity is the most critical concern with amphotericin B 1:

  • Occurs in approximately 51% of patients receiving combination therapy 2
  • Manifests as azotemia, elevated creatinine and BUN
  • Can progress to renal failure
  • Renal tubular acidosis may develop
  • Liposomal amphotericin B (LAmB) is strongly preferred over conventional amphotericin B deoxycholate for CNS infections 3, 4 specifically because it reduces nephrotoxicity while maintaining efficacy

Acute infusion-related reactions are common 1:

  • Fever, shaking chills, hypotension
  • Nausea, vomiting, headache, tachypnea
  • Occur 1-3 hours after starting infusion
  • Usually more severe with first few doses
  • Rapid IV infusion can cause hypotension, arrhythmias, and shock

Electrolyte disturbances 1:

  • Hypokalemia (potassium wasting)
  • Hypomagnesemia
  • Can potentiate cardiac arrhythmias and digitalis toxicity

Cardiovascular complications 1:

  • Cardiac arrest, myocardial toxicity
  • Ventricular dysfunction
  • Arrhythmias (especially with hypokalemia)

Flucytosine Side Effects

Bone marrow toxicity is the primary concern 5, 2:

  • Leukopenia (30% of patients in combination therapy)
  • Thrombocytopenia (22% of patients)
  • Anemia
  • Pancytopenia and fatal bone marrow aplasia in severe cases
  • Risk increases dramatically when peak serum levels exceed 100 μg/mL for ≥2 weeks 2

Gastrointestinal toxicity 5:

  • Nausea, vomiting, diarrhea (26% of patients)
  • Abdominal pain
  • Enterocolitis, ulcerative colitis
  • Gastrointestinal hemorrhage

Hepatotoxicity 5:

  • Hepatic dysfunction (13% of patients)
  • Elevated liver enzymes and bilirubin
  • Acute hepatic injury/necrosis (potentially fatal in debilitated patients)

Renal effects 5:

  • Azotemia, crystalluria
  • Elevated creatinine and BUN
  • Renal failure

Critical Drug Interaction: Synergistic Toxicity

A crucial clinical pitfall: Amphotericin B-induced renal dysfunction increases flucytosine toxicity 1, 6, 7:

  • Amphotericin B causes azotemia, which impairs flucytosine excretion
  • This leads to elevated flucytosine levels and increased bone marrow/GI toxicity
  • Even low-dose flucytosine (50 mg/kg/day) can cause severe granulocytopenia and thrombocytopenia when combined with amphotericin B 6
  • The combination increases cellular uptake of flucytosine and impairs its renal excretion 1

Overall Toxicity Profile

Combination therapy causes adverse reactions in 43-44% of patients 2:

  • Most toxicity (56%) appears within the first 2 weeks
  • 87% of toxicity occurs within the first 4 weeks
  • Fatal toxic reactions occur in approximately 2.6% of patients 2

Essential Monitoring Requirements

To minimize morbidity and mortality, intensive laboratory monitoring is mandatory 1:

Renal function (most critical):

  • Monitor frequently (at least twice weekly)
  • Serum creatinine and BUN
  • Creatinine clearance weekly
  • Adjust flucytosine dosing based on creatinine clearance 2

Electrolytes:

  • Potassium and magnesium levels regularly
  • Correct deficits promptly to prevent cardiac complications

Hematologic monitoring:

  • Complete blood counts regularly
  • Watch for leukopenia, thrombocytopenia, anemia

Flucytosine levels:

  • Measure peak serum levels weekly (2 hours post-dose)
  • Target 50-100 μg/mL; levels ≥100 μg/mL significantly increase toxicity risk 2

Liver function tests:

  • Monitor transaminases and bilirubin regularly

Risk Mitigation Strategies

Use liposomal amphotericin B preferentially 3, 4:

  • Significantly reduces nephrotoxicity compared to conventional formulation
  • Strongly recommended for CNS infections by current guidelines
  • Dose: 3-4 mg/kg/day IV (or ABLC 5 mg/kg/day)

Optimize flucytosine dosing 2:

  • Initial dose based on creatinine clearance:
    • CrCl >50 mL/min: 100 mg/kg/day (divided into 4 doses)
    • CrCl 26-50 mL/min: 75 mg/kg/day
    • CrCl 13-25 mL/min: 37 mg/kg/day
  • Adjust based on renal function changes and serum levels

Supportive measures 1:

  • Hydration and sodium repletion before amphotericin B may reduce nephrotoxicity
  • Supplemental alkali medication may decrease renal tubular acidosis
  • Avoid other nephrotoxic medications when possible

Duration considerations 4:

  • Induction therapy typically 2 weeks minimum
  • Four-week regimens show similar toxicity rates to six-week regimens 2
  • Shorter induction (2 weeks) followed by fluconazole consolidation reduces cumulative toxicity exposure

Clinical Context

Despite these significant toxicities, the combination of amphotericin B plus flucytosine remains the gold standard for CNS fungal infections 3, 4 because it:

  • Improves survival compared to amphotericin B alone 8
  • Achieves faster fungal clearance from CSF 8
  • Reduces mortality by approximately 39% at 70 days 8

The survival benefit outweighs the toxicity risks in life-threatening CNS fungal infections, but requires vigilant monitoring and proactive management of adverse effects.

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.